Pancreatic Neuroendocrine Tumor G1 C2987241
A slow-growing tumor of hormone-producing cells in the pancreas. Surgery can often remove it, and outlook is generally favorable.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Hypoglycemia
Abdominal pain
(gastrointestinal)Generalized symptoms
(oncologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Flushing
(gastrointestinal)Jaundice
(gastrointestinal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Active Surveillance
Regular imaging (CT/MRI) and biomarker monitoring for small, non-functioning pancreatic NETs G1 to assess tumor behavior over time.
Dietary counseling and physical activity plan
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Tumor Resection
Surgical removal of the pancreatic tumor, either via partial pancreatectomy or enucleation, typically recommended for tumors causing symptoms or showing growth.
Additional treatment options
Somatostatin Analogues
Long-acting injectable medications that help control symptoms from hormone-secreting tumors and may have anti-proliferative effects.
medicationSpecialized Nutritional Support
Dietitian-guided nutrition plan addressing pancreatic enzyme insufficiency and managing digestive symptoms associated with pancreatic tumors.
dietaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Pancreatic Neuroendocrine Tumor G1 C2987241?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines for the Management of Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153-171.
Yao JC, Hassan M, Phan A, et al. One Hundred Years After "Carcinoid": Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J Clin Oncol. 2008;26(18):3063-3072.
Yao JC, Shah MH, Ito T, et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med. 2011;364(6):514-523.
Zhang MF, Xu D, Guo Y, et al. Prognostic Role of Surgical Resection for Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Pancreas. 2019;48(10):1273-1282.
Medication Comparisons
Compare medications used to treat Pancreatic Neuroendocrine Tumor G1 C2987241. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy